RESUMO
OBJECTIVE: The aim of this study is to investigate potential differences in pregnancy, delivery, and neonatal outcomes between two hyperandrogenic conditions in reproductive-aged women; polycystic ovary syndrome (PCOS) and congenital adrenal hyperplasia (CAH). DESIGN: Retrospective population-based study with data from the Health Care Cost and Utilization Project-Nationwide Inpatient Sample database (HCUP-NIS) from 2004 to 2014. SUBJECTS: 14,881 women with polycystic ovary syndrome (PCOS) and 298 women with congenital adrenal hyperplasia (CAH). MAIN OUTCOME MEASURES: Gestational diabetes mellitus, placenta previa, pregnancy-induced hypertension, gestational hypertension, preeclampsia, eclampsia, preeclampsia and eclampsia superimposed on hypertension, preterm birth, preterm premature rupture of membrane, abruptio placenta, chorioamnionitis, mode of delivery, maternal infection, hysterectomy, blood transfusion, venous thromboembolism (deep vein thrombosis and pulmonary embolism during pregnancy, intrapartum, or postpartum), maternal death, chorioamnionitis, septicemia during labor, postpartum endometritis, septic pelvic, peritonitis, small for gestational age, congenital anomalies, intrauterine fetal demise. RESULTS: After adjusting for potential confounders we found that women with PCOS were at increased risk of developing pregnancy-induced hypertension (adjusted OR=1.76; 95% CI: 1.12-2.77; p=0.015) and gestational diabetes (adjusted OR=1.68; 95% CI: 1.12-2.52; p=0.012) when compared to women with CAH. Contrary women with CAH were at increased risk for delivery via cesarean section (adjusted OR 0.59; 95% CI: 0.44-0.80; p<0.001) and small for gestational age neonates (adjusted OR 0.32; 95% CI: 0.20-0.52; p<0.001). CONCLUSION: This study is the first to directly compare obstetrical and neonatal outcomes between patients with PCOS and CAH. Despite the similar phenotypes and some common hormonal and biochemical profiles such as insulin resistance, hyperinsulinemia, and hyperandrogenism, our results suggest the existence of additional metabolic pathways implicated in the pathogenesis of pregnancy complications.
RESUMO
OBJECTIVE: The purpose of this scoping review was to highlight the current scientific evidence on eHealth-based information tools for menopause in terms of quality, requirements and previous intervention outcomes. METHODS: We systematically searched electronic databases (Embase, CINAHL, Cochrane Library, Global Health Database [Ovid], Web of Science, ClinicalTrials.gov [NLM], LIVIVO Search Portal [ZB MED] and Google Scholar) from 1974 to March 2022 for relevant records. RESULTS: Our search yielded 1773 records, of which 28 met our inclusion criteria. Thirteen of 28 selected studies were cross-sectional with qualitative content analysis of websites about menopause; 9 studies were cohort studies examining the impact of an eHealth intervention; two studies were randomized controlled trials comparing eHealth tools with conventional ones; and four studies were non-systematic literature reviews. CONCLUSION: This scoping review highlights the potential of eHealth-based information tools for the management of menopause and shows that most eHealth-based information tools are inadequate in terms of readability and the balanced view on information. Providers of eHealth-based information tools should pay attention to a participatory design, readability, balance of content and the use of multimedia tools for information delivery to improve understanding.
Assuntos
Menopausa , Autogestão , Telemedicina , Humanos , Telemedicina/métodos , Feminino , Autogestão/métodosRESUMO
Menopausal women with an intact uterus choosing estrogens for menopausal symptom relief require a progestogen for endometrial protection. The aim of this systematic review was to evaluate the risks of endometrial hyperplasia resp. malignancy with different progestogens used in combined MHT. Overall, 84 RCTs were included. We found that 1) most studies were done with NETA, followed by MPA, MP and DYD and LNG, 2) most progestogens were only available as oral formulations, 3) the most frequently studied progestogens (oral MP, DYD, MPA, oral and transdermal NETA, transdermal LNG) were assessed in continuously as well as in sequentially combined MHT regimens, 4) FDA endometrial safety criteria were only fulfilled for some progestogen formulations, 5) most studies demonstrated endometrial protection for the progestogen dose and time period examined. However, 6) study quality varied which should be taken into account, when choosing a combined MHT, especially if off-label-use is chosen.
Assuntos
Hiperplasia Endometrial , Progestinas , Feminino , Humanos , Progestinas/uso terapêutico , Endométrio/patologia , Terapia de Reposição Hormonal , Hiperplasia Endometrial/induzido quimicamente , Hiperplasia Endometrial/prevenção & controle , Hiperplasia Endometrial/tratamento farmacológico , Menopausa , Terapia de Reposição de Estrogênios/efeitos adversosRESUMO
Although the utility of diagnostic cardiac catheterization in the clinical setting has diminished over the last years, due to the emergence of noninvasive imaging modalities, such as echocardiography, magnetic resonance imaging and computed tomography, catheterization for diagnostic reasons still constitutes a valuable tool in certain parts in the workup of pediatric heart disease. As a result, awareness of the main aspects of diagnostic catheterization is of great importance for the clinical cardiologist. In this article, the main variables measured and the main actions performed during diagnostic cardiac catheterization in children are discussed.
Assuntos
Cateterismo Cardíaco , Cardiopatias/diagnóstico , Cateterismo Cardíaco/métodos , Criança , Ecocardiografia/métodos , Humanos , Imageamento por Ressonância Magnética/métodos , Tomografia Computadorizada por Raios XRESUMO
In an era when less invasive techniques are favored, therapeutic cardiac catheterization constantly evolves and widens its spectrum of usage in the pediatric population. The advent of sophisticated devices and well-designed equipment has made the management of many congenital cardiac lesions more efficient and safer, while providing more comfort to the patient. Nowadays, a large variety of heart diseases are managed with transcatheter techniques, such as patent foramen ovale, atrial and ventricular septal defects, valve stenosis, patent ductus arteriosus, aortic coarctation, pulmonary artery and vein stenosis and arteriovenous malformations. Moreover, hybrid procedures and catheter ablation have opened new paths in the treatment of complex cardiac lesions and arrhythmias, respectively. In this article, the main therapeutic utilities of cardiac catheterization in children are discussed.
Assuntos
Cateterismo Cardíaco/métodos , Cateterismo Cardíaco/tendências , Cardiopatias Congênitas/terapia , Coartação Aórtica/terapia , Ablação por Cateter , Criança , Permeabilidade do Canal Arterial/terapia , Desenho de Equipamento , Átrios do Coração/cirurgia , Comunicação Interatrial/terapia , Doenças das Valvas Cardíacas/terapia , Humanos , Artéria Pulmonar , Estenose de Veia Pulmonar/terapia , Doenças VascularesRESUMO
INTRODUCTION: To investigate the immunohistochemical expression of claudin-1, claudin-3, and claudin-4 in triple-negative breast carcinomas and compare it with several clinicopathologic parameters as well as their expression in luminal cancers. MATERIALS AND METHODS: A total of 128 cases of breast carcinoma were included in the study. For all these cases, immunohistochemistry for estrogen and progesterone receptors, Ki-67, and Her2 had already been performed, whereas Her2 2+ cases had been further characterized as positive or negative for Her2 amplification with the chromogenic in situ hybridization technique. Seventy-six tumors were triple negative. The remaining 52 were luminal cancers. All tumors were evaluated for the expression of claudin-1, claudin-3, and claudin-4. RESULTS: In the triple-negative group, the positive expression of claudin-3 and claudin-4 was related to unfavorable and favorable prognostic factors, respectively. Claudin-1 was not related to any parameter under evaluation. In the luminal cancer group, claudin-4 positivity was related to a shorter disease-free survival, whereas the inverse was observed for claudin-3. Moreover, all 3 claudins increased with increase of the grade and Ki-67 value in the luminal cancers. CONCLUSION: A distinct prognostic significance in the expression of claudin-3 and mostly of claudin-4 between triple-negative and luminal breast carcinomas was identified. Specifically, in triple-negative carcinomas, claudin-4 positivity could probably be considered as a biomarker of favorable prognosis, whereas in luminal cancers with claudin-4-positive expression, the administration of targeted therapy should eventually be part of the patients' management in the near future.